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Objectives: For a recent health technology appraisal in the treatment of chronic 
idiopathic constipation, direct evidence of the effectiveness of a new intervention 
(lubiprostone) against the standard of care (prucalopride) was not available. The 
aim of this study was to review the available data from clinical trials and perform 
indirect comparisons between the two treatments where possible. MethOds: A 
literature search (in Medline and other databases) was conducted in December 
2013 for trials of lubiprostone or prucalopride. Data for any comparable endpoints 
were extracted from the papers, and indirect comparisons performed using the 
Bucher method. Results: Four clinical trials for lubiprostone were identified (three 
company-sponsored, and a small clinician-led trial), as well as three company-
sponsored clinical trials for prucalopride. After data extraction, indirect compari-
sons were possible for seven different endpoints, including the primary efficacy 
parameter of the lubiprostone studies (Spontaneous Bowel Movements; the relative 
risk was 1.12 in favour of lubiprostone, 95% CI 0.77-1.64). Other endpoints included 
the primary efficacy parameter of the prucalopride studies (Spontaneous Complete 
Bowel Movements), and a range of symptom comparisons. In total, five of the seven 
indirect comparisons favoured lubiprostone, with statistical significance reached 
in favour of lubiprostone once and prucalopride once. cOnclusiOns: The indirect 
comparisons showed that lubiprostone is likely to be at least as effective as pru-
calopride, with numerical superiority in five out of seven comparisons. However, 
the number of feasible indirect comparisons on a range of endpoints raises a wider 
question: which to use in cost-effectiveness modelling? Although analyses gener-
ally have a ‘base case’, each of the indirect comparisons adds different information 
about the relative efficacy of the two products. Given the range of endpoints with 
associated relative risks, to reduce these to a single comparison (as is current prac-
tice) may omit important and relevant information about relative efficacy.
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Objectives: Chronic hepatitis C (CHC) is a major public health problem contributing 
to more than 86,000 premature deaths in Europe. Pegylated interferon-α plus ribavirin 
(PR) based therapy, including regimens with boceprevir (BOC) or telaprevir (TVR) in 
HCV genotype-1 patients, have failed to provide more extensive therapeutic ben-
efit leaving space for substantial outcomes improvement. Sofosbuvir (SOF) – a pan-
genotypic RNA polymerase inhibitor – has shown unprecedented sustained virologic 
response rates and tolerability profiles. The objective of this study was to estimate SOF 
contribution to public health by exhausting CHC therapeutic efficiency. MethOds: 
Therapeutic efficiency was defined as maximum capacity to benefit from treatment in 
terms of life years (LY) relative to the general population’s life expectancy. The natural 
history of CHC and treatment implication was modelled with a discrete-time Markov 
allowing for long term assessment in terms of HCV genotype, fibrosis progression, HIV 
co-infection status and previous treatment experience. Treatment options compared 
were dependent on interferon eligibility/tolerance and genotype: PR, SOF/PR, BOC/
PR and TVR/PR in elegible/tolerant patients (BOC/TRV regimens in genotype-1 only; 
SOF/ribavirin in genotype-2). For ineligible/intolerant patients, comparison of SOF/
ribavirin was performed against lack-of-therapy. Results: In mono-infected HCV 
genotype-1 patients SOF/PR treatment is estimated to result in 4.3 LY, 7.0 LY or 8.0 
LY gained in comparison to TRV/PR, BOC/PR or PR, respectively. In genotype-1 and 
genotype-2 HIV-coinfected patients elegible for interferon treatment, the estimated 
LY gained with SOF treatment is 11.8yrs and 5.0yrs, respectively. In patients ineligible 
for interferon treatment, SOF is expected to almost double life expectancy irrespective 
of the genotype, with therapeutic efficiency ranging from 79% to 95%. In co-infected 
patients, therapeutic efficiency of SOF is expected to range between 84.3% and 92.4% 
of general population life expectancy. cOnclusiOns: Sofosbuvir-containing regi-
mens are expected to maximize years of life lived and maximize efficiency relative 
CHC patients residual life expectancy.
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Objectives: Studies have shown that irritable bowel syndrome (IBS) and its subtype 
with constipation (IBS-C) are associated with poorer HRQoL, decreased work produc-
tivity and increased health care utilization. However, no studies have compared the 
burden of IBS-C to similar chronic conditions. Objective was to evaluate burden of 
IBS-C compared with no functional gastrointestinal disorders (non-FGID), asthma, 
migraine, and rheumatoid arthritis (RA), on HRQoL, work productivity and health 
care utilization. MethOds: Data come from the 2011 National Health and Wellness 
Survey (nationally representative sample of adults including the US, UK and France), 
which includes health-related topics such as HRQoL (SF-12 Health Survey), work 
productivity (Work Productivity and Activity Impairment) and health care utiliza-
to compare two large commercial databases focusing on CHC patient characteristics 
and treatment patterns. MethOds: We analyzed the Japan Medical Data Center 
(JMDC) database containing employer-based health insurance claims and the 
Medical Data Vision (MDV) database containing administrative data from acute care 
hospitals. Patients aged 20 years or above and diagnosed with CHC were included in 
the study. Patients co-infected with hepatitis B and/or human immunodeficiency 
viruses were excluded. Patient characteristics and treatment patterns for CHC were 
compared. Results: 3,590 (JMDC) and 29,702 (MDV) confirmed CHC patients were 
included in the analysis. Patients in JMDC were younger than those in MDV (age 
51.6±11.9 and 63.2±13.4) and had fewer comorbidities (Charlson Comorbidity Index 
1.3±1.7 and 1.9±2.1). More patients in JMDC were found to have prior CHC treatment 
(37.2%) than in MDV (24.6%). With an index date of September 2011, about a third of 
the patients (n= 1,271, 35.4%; JMDC and n= 9,791, 33.0%; MDV) received treatments for 
CHC, comprised of 10.2% (n= 365; JMDC) and 5.5% (n= 1,620; MDV) on antiviral treat-
ments (interferon or direct acting antiviral combinations) and 25.2% (n= 906; JMDC) 
and 27.5% (n= 8,171; MDV) on liver protection drugs only. Among patients treated 
with triple therapy (telapravir/peginterferon/ribavirin), the mean total treatment 
duration was 19.3 weeks (JMDC) versus 21.9 weeks (MDV). The mean duration of tel-
aprevir therapy was 10.8 weeks (JMDC) and 10.1 weeks (MDV), followed by 11.7 weeks 
(JMDC) and 14.1 weeks (MDV) of peginterferon/ribavirin therapy. cOnclusiOns: 
Both databases found low treatment rates for CHC. Although the findings are con-
sistent, there are differences in database populations and treatment patterns that 
warrant further research. Using these administrative databases for real-world 
research may be useful depending on research objectives.
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Objectives: The aim of this study is to give an overview of the treatment available 
for the patients with Hepatitis C Virus (HCV) through the segmentation of HCV 
patients in Italy. MethOds: The study was carried out in 9 hepatology centers, 
treating HCV patients in 9 Italian Regions. The structures selected constitute a 
representative sample of the Italian scenario, being Centers of Excellence in HCV 
management in northern, southern, and center of Italy (representing about 24% 
of the 2.000 patients treated with first generation Triple Therapy in Italy according 
to AIFA Data). The patients’ distribution has been investigated in terms of fibrosis 
stage (F0 to F4), therapy type (Triple, TT, or Double therapy, DT) and treatment 
status (naive or experienced patients). Results: Data (collected from structures 
and Workshop of Pharmacoeconomics in Hepatology) show that HCV patients 
are more concentrated in the two fibrosis stage extremes: 43% in F0-F1 Range, 
23% in F2, 32% in F3-F4 Range and 2% unclassified. Data about drug administra-
tion demonstrate that, at national level, patients are equally distributed between 
therapy type (56% TT and 44% DT) and treatment status (49% naive and 51% expe-
rienced). On the contrary, at Regional level many differences were found in all of 
the three parameters examined. In the structure investigated in Campania, for 
example, 72% of patients receive TT and 76% are experienced, while in Lazio 72% 
of patients receive DT and 72% are naive. Furthermore, considering the fibrosis 
stage, the 46% of patients treated in a center operating in Bari is in the range 
F3-F4, whilst in the center in Milan the 56% of the HCV patients treated is in range 
F0-F1. cOnclusiOns: The study demonstrate that, concerning the treatment of 
HCV, there are significant differences among the hepatology centers, both in terms 
of patients’ health status and therapy pathways.
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Objectives: Hepatitis C virus (HCV) infection resulting in chronic liver disease has 
an estimated prevalence in Belgium of 0,87% (Beutels, 1997) with 59% of patients 
having genotype 1 HCV (GT1), 6% GT2, 19% GT3 and 16% GT4-5-6. Sofosbuvir 
(SOF), a novel HCV treatment, has demonstrated high rates of sustained virological 
response (SVR) when given with ribavirin to subjects with chronic HCV infections 
(all GT’s). The objective of this analysis was to assess the cost-effectiveness of 
sofosbuvir vs SoC in the treatment of chronic hepatitis C (CHC) in the following 
indications: GT 1 (Treatment Naïve (TN), INF-eligible and IFN-ineligible patients); 
GT2 & 3 (TN & Treatment Experienced (TE), both INF-eligible and IFN-ineligible 
patients) and GT 4/5/6, treatment-naïve patients in Belgium. Patients ineligible to 
IFN have no treatment options today. MethOds: Based on a Markov model, this 
cost-utility analysis models the cost-effectiveness of SOF versus SoC in Belgium 
from the perspective of the RIZIV/INAMI and taking into account the proposed 
reimbursement criteria for SOF in Belgium and the guidelines of the Knowledge 
Centre (KCE) (KCE report 78C, 2008). Results: Weighted ICER’s were calculated 
taking into account patient eligibility for treatment with IFN and treatment 
duration with SOF: GT 1, 3, 4, 5 or 6 patients who are IFN-eligible and are being 
treated with SOF (+ subcutaneous pegylated interferon-alpha (IFN-α ) plus daily 
oral ribavirin (RBV)) for 12 weeks (€ 19,954/QALY); GT 1, 3, 4, 5 or 6 patients who are 
IFN-ineligible due to intolerance and/or contra-indications and are being treated 
with SOF (+ RBV) for 24 weeks (€ 35,086/QALY) and GT 2 patients that are being 
treated with SOF (+ RBV) for 12 weeks (€ 28,121/QALY). Overall, the weighted PAN-
genotypic ICER was € 21,651. cOnclusiOns: PAN-genotypic cost-effectiveness 
has been demonstrated for sofosbuvir in comparison to the current standard of 
care in HCV in Belgium.
